180 related articles for article (PubMed ID: 9023642)
21. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients.
Thunnissen PL; Sizoo W; Hendriks WD
Neth J Med; 1991 Aug; 39(1-2):84-91. PubMed ID: 1660108
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of antifungal prophylaxis with oral itraconazole solution among patients receiving corticosteroids: who should be given prophylaxis?
Iriyama N; Matsukawa Y; Miura K; Inomata H; Hirabayashi Y; Hatta Y; Horikoshi A; Takeuchi J
J Infect Chemother; 2011 Dec; 17(6):744-9. PubMed ID: 21523410
[TBL] [Abstract][Full Text] [Related]
23. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.
Schuler U; Bammer S; Aulitzky WE; Binder C; Böhme A; Egerer G; Sandherr M; Schwerdtfeger R; Silling G; Wandt H; Glasmacher A; Ehninger G
Onkologie; 2007 Apr; 30(4):185-91. PubMed ID: 17396041
[TBL] [Abstract][Full Text] [Related]
25. [Itraconazole for secondary prophylaxis of invasive fungal infection in patients undergoing chemotherapy and stem cell transplantation].
Shi JM; Wang C; Zhou YH; Yu K; Du X; Luo Y; Cai Z; He JS; Ye XJ; Zhang J; Xie WZ; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):413-6. PubMed ID: 23688752
[TBL] [Abstract][Full Text] [Related]
26. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies.
Tricot G; Joosten E; Boogaerts MA; Vande Pitte J; Cauwenbergh G
Rev Infect Dis; 1987; 9 Suppl 1():S94-9. PubMed ID: 3027853
[TBL] [Abstract][Full Text] [Related]
27. Clinical effectiveness of itraconazole as antifungal prophylaxis in AML patients undergoing intensive chemotherapy in the modern era.
Keighley CL; Manii P; Larsen SR; van Hal S
Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):213-217. PubMed ID: 27830376
[TBL] [Abstract][Full Text] [Related]
28. [Prevention of aspergillosis with itraconazole in neutropenic patients: importance of drug monitoring].
Cheymol G; Poirier JM
Bull Acad Natl Med; 1999; 183(2):371-80; discussion 380-1. PubMed ID: 10371783
[TBL] [Abstract][Full Text] [Related]
29. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol.
Krcmery V; Mateicka F; Kunová A; Spánik S; Gyarfás J; Sycová Z; Trupl J
Support Care Cancer; 1999 Jan; 7(1):39-43. PubMed ID: 9926973
[TBL] [Abstract][Full Text] [Related]
30. [Prophylaxis against mycoses in neutropenic patients].
Arning M; Aul C
Mycoses; 1994; 37 Suppl 2():70-6. PubMed ID: 7541892
[TBL] [Abstract][Full Text] [Related]
31. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy.
Prentice AG; Glasmacher A; Djulbegovic B
Br J Haematol; 2006 Mar; 132(5):656-8; author reply 658-9. PubMed ID: 16445845
[No Abstract] [Full Text] [Related]
32. The role of primary antifungal prophylaxis in patients with haematological malignancies.
Pagano L; Caira M
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
[TBL] [Abstract][Full Text] [Related]
33. Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen.
Poirier JM; Hardy S; Isnard F; Tilleul P; Weissenburger J; Cheymol G
Ther Drug Monit; 1997 Oct; 19(5):525-9. PubMed ID: 9357095
[TBL] [Abstract][Full Text] [Related]
34. Prophylaxis and treatment of fungal infections associated with haematological malignancies.
Ascioglu S; de Pauw BE; Meis JF
Int J Antimicrob Agents; 2000 Aug; 15(3):159-68. PubMed ID: 10926437
[TBL] [Abstract][Full Text] [Related]
35. Fungal surveillance cultures during antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia.
Glasmacher A; Hahn C; Molitor E; Sauerbruch T; Schmidt-Wolf IG; Marklein G
Mycoses; 1999; 42(5-6):395-402. PubMed ID: 10536431
[TBL] [Abstract][Full Text] [Related]
36. Plasma Concentration of Itraconazole in Patients With Hematologic Malignancies Treated With Itraconazole Oral Solution.
Marumo A; Miyawaki S; Dan N; Ishiyama K
Ther Drug Monit; 2017 Jun; 39(3):229-234. PubMed ID: 28445212
[TBL] [Abstract][Full Text] [Related]
37. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
Vardakas KZ; Michalopoulos A; Falagas ME
Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
[TBL] [Abstract][Full Text] [Related]
38. Itraconazole in neutropenic patients.
van't Wout JW
Chemotherapy; 1992; 38 Suppl 1():23-6. PubMed ID: 1319311
[TBL] [Abstract][Full Text] [Related]
39. Itraconazole to prevent fungal infections in chronic granulomatous disease.
Gallin JI; Alling DW; Malech HL; Wesley R; Koziol D; Marciano B; Eisenstein EM; Turner ML; DeCarlo ES; Starling JM; Holland SM
N Engl J Med; 2003 Jun; 348(24):2416-22. PubMed ID: 12802027
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies: an open-lable, multicenter, observational trial in a Chinese cohort.
Cheng S; Zhou JF; Zou P; Huang XJ; Jin J; Shen ZX
Chin Med J (Engl); 2011 Nov; 124(22):3670-5. PubMed ID: 22340222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
